What is HC Wainwright’s Forecast for Metagenomi Q4 Earnings?

Metagenomi, Inc. (NASDAQ:MGX) – Equities researchers at HC Wainwright raised their Q4 2024 earnings estimates for shares of Metagenomi in a report issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.52) for the quarter, up from their previous forecast of ($0.69). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Metagenomi’s Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.48) EPS.

Several other analysts also recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Metagenomi in a research note on Wednesday, November 20th. BMO Capital Markets decreased their target price on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.50.

Metagenomi Stock Up 3.8 %

MGX opened at $1.89 on Monday. The business’s 50 day moving average is $2.06 and its 200-day moving average is $3.69. Metagenomi has a twelve month low of $1.61 and a twelve month high of $12.74.

Institutional Trading of Metagenomi

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers purchased a new stake in shares of Metagenomi during the second quarter valued at $26,000. BNP Paribas Financial Markets boosted its holdings in shares of Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares during the period. Virtu Financial LLC purchased a new position in shares of Metagenomi in the third quarter worth approximately $33,000. XTX Topco Ltd purchased a new position in shares of Metagenomi in the second quarter worth approximately $66,000. Finally, Resolute Advisors LLC raised its holdings in shares of Metagenomi by 165.0% during the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock valued at $108,000 after acquiring an additional 16,500 shares during the period.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.